Search Within

Department of Medicine

Formats
  1. Journal Article (19626)
  2. Meeting Abstract (16084)
  3. Review (1160)
  4. Book Section (934)
  5. Editorial (612)
  6. Research Letter (316)
  7. Conference Paper (301)
  8. Guidelines (298)
  9. Correspondence (237)
  10. Miscellaneous (91)
  11. Book Whole (61)
Groups
  1. Solid Tumor Oncology Division (22375)
  2. Hematologic Malignancies, Division of (13310)
  3. Center for Hematologic Malignancies (11084)
  4. GSK Faculty (10659)
  5. Survivorship Research (9357)
  6. Division of Subspecialty Medicine (7562)

More Groups

People
  1. Robert Motzer (1252)
  2. Howard Scher (1133)
  3. Sergio Giralt (1069)
  4. Miguel-Angel Perales (943)
  5. Clifford Hudis (906)
  6. Jedd Wolchok (905)

More People

Years
  1. 2025 (1167)
  2. 2024 (2293)
  3. 2023 (2452)
  4. 2022 (2621)
  5. 2021 (2534)
  6. 2020 (2563)

More Years

Publications
  1. Journal of Clinical Oncology (6125)
  2. Blood (3722)
  3. Annals of Oncology (1411)
  4. Cancer Research (1238)
  5. Clinical Cancer Research (904)
  6. Biology of Blood and Marrow Transplantation (679)

More Publications

Publishers
  1. American Society of Clinical Oncology (6458)
  2. Elsevier Inc. (4217)
  3. American Society of Hematology (4004)
  4. American Association for Cancer Research (2898)
  5. Oxford University Press (2306)
  6. Nature Publishing Group (2122)

More Publishers

Results (39720)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A comprehensive and collaborative workflow to establish customized endpoints and biomarkers for immunotherapy trials
    Meeting Abstract

    Vidal, E. H.; Mcavoy, D.; Vallone, A.; Thomsen, M.; Maslak, P.; Harris, A.; Oved, J.; Hosszu, K.; Boelens, J. J.
    Cytotherapy (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab by age and frailty in patients with relapsed/refractory multiple myeloma (RRMM): Subgroup analysis from MagnetisMM-3
    Meeting Abstract

    Raje, N.; Leleu, X.; Lesokhin, A.; Mohty, M.; Nooka, A. K.; Leip, E.; Conte, U.; Viqueira, A.; Manier, S.
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Idecabtagene vicleucel (ide-cel) versus standard regimens in patients with triple-class-exposed (TCE) relapsed and refractory multiple myeloma (RRMM): A KarMMa-3 analysis in high-risk subgroups
    Meeting Abstract

    Patel, K.; Rodríguez-Otero, P.; Manier, S.; Baz, R.; Raab, M. S.; Cavo, M.; Callander, N.; Costa, L. J.; Moreau, P.; Solomon, S.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Early mortality in multiple myeloma- A SEER data analysis
    Meeting Abstract

    Wei, J.; Shastri, A.; Sica, R. A.; Mantzaris, I.; Kornblum, N.; Shah, U.; Janakiram, M.; Gritsman, K.; Verma, A.; Goldfinger, M.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Belantamab mafodotin for relapsed or refractory multiple myeloma: A real-world observational study update
    Meeting Abstract

    Hultcrantz, M.; Kleinman, D.; Vij, R.; Escalante, F.; Delforge, M.; Kotowsky, N.; Bitetti, J.; Boytsov, N.; Camadoo-O'Byrne, L.; Happ, L. P.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, for patients with relapsed/refractory multiple myeloma (RRMM): Extended follow-up and biweekly administration from the MagnetisMM-3 study
    Meeting Abstract

    Mohty, M.; Tomasson, M. H.; Arnulf, B.; Bahlis, N. J.; Prince, H. M.; Niesvizky, R.; Rodríguez-Otero, P.; Martínez-Lopez, J.; Koehne, G.; Jethava, Y.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Efficacy and safety of elranatamab in patients with relapsed/refractory multiple myeloma (RRMM) and prior B-cell maturation antigen (BCMA)-directed therapies: Pooled analysis from MagnetisMM Studies
    Meeting Abstract

    Nooka, A. K.; Lesokhin, A. M.; Mohty, M.; Niesvizky, R.; Maisel, C.; Arnulf, B.; Larson, S. M.; Varshavsky-Yanovsky, A. N.; Leleu, X.; Karlin, L.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Lin, Y.; Martin, T.; Usmani, S.; Berdeja, J.; Jakubowiak, A.; Agha, M.; Cohen, A.; Deol, A.; Htut, M.; Lesokhin, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • Pirtobrutinib in covalent BTK inhibitor pre-treated mantle cell lymphoma: Updated results and subgroup analysis from the phase 1/2 BRUIN study with >3 years follow-up from start of enrollment
    Meeting Abstract

    Wang, M. L.; Shah, N. N.; Jurczak, W.; Zinzani, P. L.; Eyre, T. A.; Cheah, C. Y.; Ujjani, C. S.; Izutsu, K.; Ma, S.; Flinn, I.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save
  • A multi-institutional prospective cohort study of minimal residual disease in peripheral T-cell lymphoma: Impact of autologous stem cell transplant (ASCT)
    Meeting Abstract

    Foley, N.; Russler-Germain, D.; Watkins, M.; Jacobsen, E.; Moskowitz, A.; Cashen, A.; Fehniger, T.; Kahl, B.; Bartlett, N.; Ghobadi, A.; more...
    Clinical Lymphoma, Myeloma and Leukemia (2023)

    Fulltext@MSK | Save